Michael Holmes

Chief Scientific Officer at Tessera Therapeutics

Michael Holmes is the Chief Scientific Officer at Tessera Therapeutics, a biotechnology company pioneering Gene Writing™ technology.1 2 He joined Tessera in December 2021, bringing over 20 years of experience in developing and clinically translating genome editing and gene therapy strategies for treating inherited and acquired diseases.1 3

Career Highlights

Dr. Holmes has an impressive track record in translating genomic engineering technologies into product candidates, having led ten therapeutic programs across ex vivo and in vivo therapies.1 2 Prior to Tessera, he served as:

Chief Scientific Officer at Ambys Medicines, leading research and development of novel therapies for severe liver diseases1 3
Senior Vice President and Chief Technology Officer at Sangamo Therapeutics, Inc., where he worked for 17 years and was heavily involved in research and pipeline development of genetic therapies1 3

Scientific Contributions

Dr. Holmes has made significant contributions to the field of genetic medicine:

Authored over 60 publications in genome editing and gene regulation1 3
Listed as an inventor on more than 40 issued and pending U.S. patents related to genome editing and targeted gene regulation technologies1 3
Led efforts resulting in the first-ever clinical candidate of a genome editing-based therapy2
Developed the SB-525 human factor 8 protein (hFVIII) cDNA program, achieving the highest reported level of hFVIII in animal studies2

Education and Recognition

Ph.D. in Molecular and Cell Biology from the University of California, Berkeley1 2
B.S. in Molecular Biology from the University of California, San Diego1 2
Named one of "The World's Most Influential Scientific Minds" in 2014 and 2015 by Thomas Reuters1 3
Included in the 2020 list of Highly Cited Researchers by Clarivate1 3

At Tessera Therapeutics, Dr. Holmes leads the development of novel technologies and transformative therapies, leveraging his extensive experience in genome engineering to advance the company's Gene Writing™ platform.2 3